Author Affiliations: Toxin Science Ltd, Wrexham, Wales, United Kingdom, and Botulinum Research Center, University of Dartmouth, Dartmouth, Massachusetts.
The recent publication from Yu et al,1 examining 2 botulinum toxin products for the treatment of lateral orbital rhytids, shows an apparent clinical distinction between the products. AbobotulinumtoxinA (Dysport; Medicis) demonstrated a trend toward greater improvement at day 2 and statistically significant improvements at days 4 and 6, all at maximum contraction.1 This report seems to be almost a duplicate of that previously published by the same group,2 but the number of injection points has been reduced from 5 to 4 in the later report.1 The 2 studies seem to be part of the same trial.1
Pickett A. Inability of Speculation to Explain Dose Effect Differences Between Botulinum Toxin Products. Arch Facial Plast Surg. 2012;14(6):467–468. doi:10.1001/jamafacial.2013.366
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.